Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer – evaluation of the prognostic significance of these agents by Sulkowski, Stanislaw et al.
Clin Chem Lab Med 2009;47(11):1439–1445  2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.305 2009/296
Article in press - uncorrected proof
Hypoxia related growth factors and p53 in preoperative
sera from patients with colorectal cancer – evaluation
of the prognostic significance of these agents
Stanislaw Sulkowski1, Andrzej Wincewicz2,*,
Bogdan Zalewski3, Waldemar Famulski2,
Joanna Maria Lotowska1, Mariusz Koda1,
Maria Elzbieta Sobaniec-Lotowska2, Michal
Mysliwiec4, Marek Baltaziak1, Krystyna
Pawlak4 and Mariola Sulkowska1
1 Department of General Pathomorphology, Medical
University of Bialystok, Bialystok, Poland
2 Department of Medical Pathomorphology, Medical
University of Bialystok, Bialystok, Poland
3 Department of General and Gastrointestinal
Surgery, Medical University of Bialystok, Bialystok,
Poland
4 Department of Nephrology and Transplantology,
Medical University of Bialystok, Bialystok, Poland
Abstract
Background: Insulin-like growth factor-I (IGF-I) and
vascular endothelial growth factor (VEGF) belong to
a group of hypoxia related proteins. IGF-I induces
expression of VEGF and decomposes wild type p53
in cancer cell lines. The goal of our study was to eval-
uate serum IGF-I, VEGF and p53 with respect to over-
all and disease free survival of patients with colorectal
cancer (CRC) patients compared with healthy
volunteers.
Methods: Preoperative blood samples from 125
patients with CRC and 16 healthy volunteers were
examined using ELISA for serum IGF-I, p53 and VEGF
concentrations.
Results: Concentrations of p53 and VEGF were signif-
icantly higher in CRC patients than in controls
(p-0.0006 and p-0.0001, respectively). IGF-I was not
statistically different between both groups. Serum
IGF-I showed negative correlation with p53 in CRC
patients (p-0.04, rs–0.193). IGF-I and VEGF showed
negative correlation in poorly differentiated cancers
(G3) (p-0.03, rs–0.339). Patients with VEGF concen-
trations that were above average for the cancer pop-
ulation survived for a shorter period of time (ps0.065
in evaluation of overall survival and 0.071 in estima-
tion of disease-free survival during a 3-year follow-up)
compared with patients with serum VEGF lower than
the highest values seen in controls.
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Conclusions: Comparisons between serum IGF-I and
p53 appear to confirm the metabolism of p53 by
IGF-I. Serum VEGF showed prognostic significance in
our study. Serum concentrations of IGF-I and VEGF
did not show positive correlation, as expected due to
IGF-I induction of VEGF in malignant colon cell lines.
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Introduction
Insulin-like growth factor-I (IGF-I) interacts with vas-
cular endothelial growth factor (VEGF) and p53 (1, 2).
Both IGF-I and VEGF belong to a group of hypoxia
related proteins. Studies of IGF-I are important due
to its therapeutic implications in the management of
cancer. Particularly, anti-IGF-I agents such as specific
antibodies limits the development of hepatic metas-
tases of human colorectal cancer (CRC) (3). CRC is
associated with a wide array of various proteins. For
example, IGF-I, VEGF and p53 impact tumor growth
(4). VEGF is induced by IGF-I CRC cell lines (1, 5). Neo-
plastic development is restricted by the blood supply
to new tumor. VEGF is a major agent that is respon-
sible for development of new capillaries and their
differentiation into venules and arterioles in the pro-
cess of angiogenesis. VEGF has proven to be a valu-
able prognostic marker for tumor progression, and its
role has also been elucidated in colorectal carcinoma
(6, 7). Additionally, VEGF was shown to correlate with
acute-phase proteins in patients with gastroesopha-
geal cancer (8). Furthermore, preoperative and post-
operative serum concentrations of VEGF increase in
patients with CRC compared with healthy volunteers
(7, 9). These are increased even greater in patients
with metastases from CRC (9). In addition, preopera-
tive concentrations were assumed to correspond with
disease-specific and disease-free survival (9). There
is evidence for synergy of IGF-I and VEGF in the
development of the vascular network that correlates
with serum concentrations of IGF-I and VEGF in dia-
betic disorders (10) and polycystic ovary syndrome
(11). However, it should be stressed that increases in
IGF-I are not always associated with the release of
VEGF into circulation, as exemplified by conditions
such as acromegaly. In the course of this illness, there
was no upregulation of plasma VEGF despite increas-
es in IGF-I (12). In addition, IGF-I degrades wild type
p53 in one particular type of NIH-3T3 cells (2). In a
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previous study, we showed a close link between pre-
operative concentrations of p53 and VEGF in sera
from patients with CRC (13). As an inhibitor of uncon-
trolled proliferation, p53 can be considered a good
guardian of the human genome. p53 has an indispens-
able function in repairing cellular defects. In the event
that repairs fail, p53 induces apoptosis of abnormal
cells. However, p53 cannot be detected in the sera of
patients with certain cancers such as lung cancer (14).
Overexpression of p53 occurs during progression
from benign adenoma to CRC, with a prevalence for
left-sided colon cancers (15, 16). Given these findings,
our task was to reveal the relationship between IGF-I
and VEGF or p53 in sera collected preoperatively from
patients with CRC.
Materials and methods
Group of patients
Preoperative blood samples were obtained consecutively
from 125 patients with CRC (51 females and 74 males) who
qualified for tumor resection. All subjects were citizens of
the north-eastern region of Poland. Patients did not have any
prior radiotherapy or chemotherapy prior to collection of
samples. None of them was reported to suffer from diabetes
mellitus. The average age of the entire patient population
was 66 years. Patients were divided into those aged )60
years (95 patients) and those 60 years of age or less (30 indi-
viduals). Conventional histopathological parameters (includ-
ing American Joint Committee on Cancer/International
Union Against Cancer Tumor Node Metastasis stage (AJCC/
UICC TNM stage), tumor type and grade of histological dif-
ferentiation (G) were assessed independently by two patho-
logists. According to guidelines of the World Health
Organization (WHO), the primary tumors of 81 patients were
classified as moderately differentiated cancers (histological
differentiation grade (G2) and 44 individuals were deter-
mined to be poorly differentiated (G3). A diagnosis of ade-
nocarcinoma (adc) was established in 106 of the cases and
the other 19 tumors were mucinous adenocarcinomas (muc
adc). We divided patients into two groups according to
tumor location: 58 cases were found in the rectum and 67
cancers were located in the colon. We also divided all sub-
jects into two groups according to depth of tumor invasion
of intestinal wall (pT) classification: there were 10 subjects
with pT1 or pT2 (pT1qpT2) (shallowly invading tumors con-
fined to the submucosa or muscularis propria). One hundred
and fifteen primary cancers were classified as pT3 or pT4
(pT3qpT4) (deeply invading tumors that extended through
the muscularis propria). The tumor had metastasized to local
lymph nodes in 61 cases (Nq), while 64 patients were node
negative (N–) (Table 1). Blood samples from controls were
obtained from 16 healthy volunteers. There was no marked
variation in protein concentrations in the control group to
warrant further investigation. Half of the healthy volunteers
were over 60 years of age. There were equal numbers of
women and men in the control group. This study was per-
formed in agreement with the ethical standards in the latest
revision of Declaration of Helsinki from 2004 (the approval
by the Ethical Committee for studies on animals and humans
at Medical University of Bialystok). All the subjects gave their
informed consent prior to their inclusion in the study.
ELISA analysis – evaluation of serum levels
of the proteins
The serum concentrations of p53, VEGF and IGF-I were
measured using ELISA. We used serum for the evaluation
of VEGF, although there are numerous reports concerning
more precise measurement of this protein in plasma. How-
ever, the other proteins were measured in sera. Thus, we
decided to be uniform in our investigation with respect to
examination of single body fluid. However, plasma VEGF is
more representative of circulating VEGF since VEGF concen-
trations increase due to secretion of VEGF from platelets that
are activated during preparation of serum (17, 18). Although
VEGF concentrations have been reported to be much lower
in plasma compared with serum in patients with CRC, serum
concentrations do correlate with plasma concentrations (17,
18). Therefore, this was appropriate for statistical analysis
to compare serum VEGF concentrations with other serum
proteins because the proportions of VEGF do not change
with respect to the type of body fluid examined (17, 18). The
ELISA methods employed mouse monoclonal antibody
against IGF-I (human IGF-I immunoassay, Catalog Number
DG100, Qantikine R&D Systems, Inc. Minneapolis, USA),
sheep antibodies against both mutant and wild type of p53
(p53 pan ELISA, Cat. Nr.1 828 789 Roche Diagnostics GmbH,
Roche Molecular Biochemicals, Mannheim, Germany) and
biotinylated rabbit anti-human VEGF polyclonal antibodies
(human VEGF ELISA kit CatNo C-64406, PromoKine,
PromoCell GmbH, Heidelberg, Germany). Dilution factors
used were in accordance with the manufacturer’s instruc-
tions. We followed the manufacturer’s protocol for measure-
ment of serum p53 (Roche Diagnostics, Germany). Samples
were allowed to clot, centrifuged and diluted. For measure-
ment of VEGF, samples were diluted in standard as recom-
mended by the manufacturer (PromoCell GmbH, Heidelberg,
Germany). For IGF-I, serum samples were pretreated with
blue dye and an acid solution which required taking this dilu-
tion factor into consideration (R&D Systems, Inc. Minneap-
olis, USA). ELISA procedures were performed separately for
each protein using different plates. The biotin-labeled anti-
body that was attached to streptavidin-covered microtiter
plates bound the p53 molecules in 100 mL serum. This was
followed by the addition of a peroxidase labeled polyclonal
sheep antibody against p53 (700 mL of anti-p53-POD predi-
luted, Roche Diagnostics, Germany). The antibody detected
both mutant and wild type p53. VEGF molecules (using
25 mL of its solution) reacted with biotinylated rabbit anti-
human VEGF polyclonal antibody. Fifty mL of pretreated
serum was incubated with mouse monoclonal antibody
against IGF-I coated onto the wells of a microtiter plate. The
wells were washed several times. Different types of peroxi-
dase dyed p53 and IGF-I reacted with substrate – tetrame-
thylbenzidine (TMB) (200 mL of substrate solution). For
VEGF, a red product (formazan) appeared after dephospho-
rylation of NADPH to NADH. Color reactions were inhibited
with stop solutions. The absorbances were evaluated using
appropriate calibration curves and converted to p53, VEGF
and IGF-I concentrations. Measurements were performed in
duplicate.
Statistical analysis
Correlations were examined for bivariate associations using
Spearman’s rank correlation. p-Values -0.05 were consid-
ered to be statistically significant. Highly significant corre-
lation was considered in cases where coefficients of
correlation (r) had values of 0.5 or greater. Kaplan-Meier
analysis was performed to investigate overall survival rates
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Table 1 Clinical and pathological characteristics of patients.
Groups of patients n %
N
(–) 64 51.2
(q) 61 48.8
G
2 81 64.8
3 44 35.2
pT
pT1qpT2 115 92
pT3qpT4 10 8
HP type
Adc 106 84.8
Adc muc 19 15.2
Gender
Males 74 59.2
Females 51 40.8
Age
F60 years 30 24
)60 years 95 76
Site
Rectum 58 46.4
Colon 67 53.6
N, lymph node involvement; G, grading of cancer differen-
tiation; pT, depth of cancer invasion of intestinal wall; HP
type, histopathological type; adc, adenocarcinoma; adc muc,
mucinous adenocarcinoma.
of patients with higher and lower serum concentrations of
the proteins measured. The control mean concentrations of
proteins were used for classification of cases as low or high
in the estimation of overall survival. This was performed for
the 36 patients that expired by the end of this study.
Kaplan-Meier analysis was also used to evaluate statistical
significance in disease-free survival rates of patients with
higher and lower serum levels the measured proteins com-
pared with the mean values in the cancer population during
a 3-year period. The mean concentrations of proteins in
controls were used as cut-off thresholds for establishing cas-
es with low or high values in the estimation of disease-free
survival.
Results
Comparison of serum p53, IGF-I and VEGF
between CRC patients and control group
Concentrations of p53 and VEGF were significantly
higher in the serum of patients with CRC compared
with controls (p-0.0006 and p-0.0001, respectively).
IGF-I did not differ significantly between both groups
(p)0.05).
Separate comparison of serum p53, IGF-I
and VEGF in CRC patients
CRC patients who were 60 years or age of younger
had significantly higher concentrations of IGF-I com-
pared with patients over 60 years of age (p-0.0001).
Sera from male patients with CRC contained more
IGF-I, on average, than females (p-0.003). There was
no relationship between the proteins investigated
with respect to node involvement (N), depth of tumor
invasion of intestinal wall (pT), grading (G), location
of primary CRC, histological type of cancer. Compar-
isons of p53 or VEGF concentrations were not signif-
icant between groups according to age and
gender (Table 2).
Comparison of IGF-I to VEGF in CRC groups
of different clinicopathologic features
IGF-I did not correlate with VEGF in sera of CRC
patients and in the subgoups of lymph node status,
pT stage, tumor grade, histological type, age and
location of tumor.
Poorly differentiated cancers (G3) were associated
with a trend toward highly significant negative cor-
relation between concentrations of IGF-I and VEGF
(p-0.03, rs–0.339) but no statistical significance in
patients with G2 tumors (Table 2).
Linkages of IGF-I and p53 in CRC groups
of different clinicopathologic features
Serum values of p53 and IGF-I correlated negatively
for the entire group of CRC patients (p-0.04,
rs–0.193) and individuals with pT3 or pT4 (p-0.05,
rs–0.187). There was an trend towards negative
correlation but without statistical significance in pT1
or pT2 tumors (rs–0.546, p)0.05). Comparison of
serum p53 and IGF-I was statistically significant but
failed to display a negative correlation in CRC patients
with adc (rs–0.205, p-0.04). Subjects with mucinous
carcinoma did not show any linkage of this kind. A
non-significant relationship was seen between p53
and IGF-I in sera from male patients (rs–0.230,
ps0.050), and no relationship seen in female patients
with CRC. Concentrations of p53 and IGF-I showed
negative correlation but no statistical significance
between p53 and IGF-I in CRC patients’ lymph node
involvement (rs–0.242, ps0.065), in CRC subjects
more than 60 years of age (rs–0.202, ps0.067) and
in individuals with colon tumors (rs–0.233, ps0.064).
There was no significant relationship between p53 to
IGF-I in groups of N– patients, younger individuals or
those with rectal tumors (Table 2).
Survival of patients in groups of low and high
levels of studied proteins
For survival rates of patients grouped according to
low or high serum concentrations of the proteins
studied, we noted that patients with VEGF concentra-
tions above average for the cancer population had
shorter survival, achieving almost statistical signifi-
cance (ps0.065 in evaluation of overall survival) com-
pared with patients with VEGF concentrations below
the mean (;6 pg/mL in healthy controls) (Figure 1).
We also evaluated disease-free survival between
patients with VEGF concentrations lower or higher
than mean serum values seen in the cancer popula-
tion during 3 years and 9 months of follow-up
(ps0.071) (Figure 2). Similar analyses were per-
formed for p53 and IGF-I with no trend toward statis-
tical significance. No statistical difference was found
in the evaluation of differences in survival between
groups with increased or low marker concentrations
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Table 2 Comparison between IGF-I and other proteins from sera obtained preoperatively from patients with CRC. Spear-
mann’s correlation test.
Groups of patients Mean levels and SD IGF-I and VEGF IGF-I and p53
IGF-I VEGF p53 p-Value r p-Value r
Control group 81.47"37.38 5.93"1.15 16.75"18.44 NS –0.393 NS 0.020
All CRC patients 79.99"37.4 128.35"146.0 181.39"382.95 NS –0.141 -0.04 –0.193
N
(–) 83.3"39.57 113.47"124.46 144.13"312.69 NS –0.042 NS –0.123
(q) 76.51"34.96 144.22"165.63 220.54"444.46 NS –0.218 0.065 –0.242
G
2 77.56"28.65 115.73"116.91 161.90"276.09 NS 0.085 NS –0.171
3 85.76"49.56 188.75"193.12 220.26"532.45 -0.03 –0.339 NS –0.232
pT
pT1qpT2 65.07"13.15 158.52"171.34 219.67"285.54 NS –0.433 NS –0.546
pT3qpT4 81.28"38.55 125.7"144.2 178.31"390.56 NS –0.129 -0.05 –0.187
HP type
Adc 75.84"29.69 131.30"149.23 198.36"410.06 NS –0.080 -0.04 –0.205
Adc muc 103.13"61.84 112.04"129.49 84.28"120.68 NS –0.340 NS –0.228
Gender
Males 86.14"31.50 127.89"146.25 170.32"323.13 NS –0.077 -0.05 –0.230
Females 71.05"43.38 129.03"147.23 198.23"462.60 NS –0.216 NS –0.161
Age
F60 years 105.33"47.46 106.66"115.26 66.10"78.16 NS –0.149 NS –0.034
)60 years 72.31"29.78 138.15"158.78 226.11"450.04 NS –0.128 0.067 –0.202
Site
Rectum 77.74"30.40 94.95"117.87 152.63"289.38 NS –0.155 NS –0.112
Colon 81.93"42.67 157.70"162.21 207"451.10 NS –0.156 0.067 –0.233
CRC, colorectal cancer; SD, standard deviation; IGF-I, insulin-like growth factor-I; VEGF, vascular endothelial growth factor;
NS, not significant; N, lymph node involvement; G, grading of cancer differentiation; pT, depth of cancer invasion of intestinal
wall; HP type, histopathological type; adc, adenocarcinoma; adc muc, mucinous adenocarcinoma.
Figure 1 Kaplan-Meier plot showing overall survival.
ps0.065 between group VEGF-As2 and VEGF-As0. VEGF-
As2, higher concentrations of VEGF compared with the
average concentration of VEGF in all cancer patients; VEGF-
As1, VEGF in cancer patients greater than mean concentra-
tions of VEGF seen in controls, but less than average VEGF
concentrations seen in all cancer patients; VEGF-As0, VEGF
concentrations in cancer patients less than the mean VEGF
concentration seen in controls; y-axis, cumulative number of
survivors; x-axis, survival time in trimesters.
Figure 2 Kaplan-Meier plot showing disease-free survival.
ps0.071. Group 0, lower serum concentrations of VEGF
compared with the mean concentrations seen in all patients
with cancer. Group 1, higher serum concentrations of VEGF
compared with the mean concentrations seen in all patients
with cancer. y-axis, cumulative number of survivors; x-axis,
survival time in trimesters.
with respect to gender, younger or older patients, G3,
G2 tumors, pT1q2, pT3q4 cancers and groups of oth-
er different clinical and pathological features. There
were no differences in survival time for IGF-1 or p53
with respect to different age groups. Median values
and interquartile range (IQR) of proteins are present-
ed in Table 3. Receiver operating characteristic (ROC)
curve analysis did not identify survival on the basis
of VEGF, IGF-1 or p53 concentrations (data not
shown).
Discussion
Increases in circulating IGF-I predict development of
colon cancer (19). Growth of murine, cecum adcs was
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Table 3 Median values and IQR of proteins in sera obtained preoperatively from patients with CRC.
Groups of patients IGF-I VEGF p53
Median IQR Median IQR Median IQR
Control group 80.9 32.375 6 0 3 32.25
All of CRC patients 74.7 44.65 71.2 182.25 52 131.5
N
(–) 75.6 41.225 65.3 174.3 48 79
(q) 69.7 49.3 79.5 178.8 58 187
G
2 73.1 33.725 65.9 196.475 51.5 144
3 77.75 61.775 78.9 167.775 51.5 96.5
pT
pT1qpT2 69.8 19.8 77.1 204.25 163 306.5
pT3qpT4 75.05 47.9 70 180.45 51.5 113
HP type
Adc 73 44 73.6 194.1 52 141
Adc muc 100.8 60.35 59.95 128.2 36 86.75
Gender
Males 78.8 39.9 73.6 159.8 51 141.5
Females 63.85 34.375 59.4 203.4 53 117
Age
F60 years 99.5 56.3 66.5 145.6 46 62
)60 years 69.9 37.3 73.6 201.2 52 182
Site
Rectum 74.7 39.25 52.3 120.8 52 122
Colon 74.7 49.15 84.25 162.8 50 138
IQR, interquartile range; CRC, colorectal cancer; IGF-I, insulin-like growth factor-I; VEGF, vascular endothelial growth factor;
N, lymph node involvement; G, grading of cancer differentiation; pT, depth of cancer invasion of intestinal wall; HP type,
histopathological type; adc, adenocarcinoma; adc muc, mucinous adenocarcinoma.
more extensive in control mice than in liver-specific
IGF-I-deficient (LID) mice due to administration of
recombinant human IGF-I (19). In particular, the speed
of neoplastic enlargement was slower in LID mice.
Similarly, liver metastases from colon cancer were
less frequent in LID mice. Furthermore, most relevant
to our study, tumor immunoreactivity for VEGF and
vessel density correlated with serum IGF-I concentra-
tions (19). Transplantation of carcinomatous frag-
ments resulted in development of cancer in smaller
number of LID mice in comparison with a homolo-
gous amount of tumors in control mice. IGF-I forces
neoplastic progression via exertion of VEGF synthesis
in human CRC (1, 5). However, our findings contradict
any positive relationship between IGF-I and VEGF in
humans. The influence of IGF-I on colonic tumor
growth was suggested to be due to multiple factors
(4, 19). Studies of cultured cell lines were the first
to show linkage between IGF-I stimulation and VEGF
expression in human CRC (4). IGF-I stimulated tran-
scription of VEGF mRNA five-fold in COLO 205 cells.
IGF-I also augmented stability of VEGF mRNA after
exposure to actinomycin. Striking mismatches were
revealed by experiments using a monoclonal anti-
body against type I IGF receptor (aIR3). The antibody
significantly impaired the capability to promote VEGF
mRNA synthesis. However, it caused tyrosine phos-
phorylation of the b-subunit of the IGF-I receptor.
Most likely, cell proliferation and VEGF expression are
maintained via different pathways that are turned on
by IGF-I (4). In addition, we reported a significant pos-
itive correlation between IGF-I and Bax or Bak in pre-
vious work (20). That would suggest that IGF-I could
counteract survival of malignant cells. We did not find
any linkage between VEGF and IGF-I in sera from
patients with CRC. However, grade G3 was associated
with a negative trend between IGF-I and VEGF con-
centrations. Thus, the relationship between IGF-I and
VEGF during tumor growth is not clear and suggests
that further studies are needed.
It is widely known that CRCs develop faster and
more aggressively if they occur early in a life (21).
However, hereditary non-polyposis colorectal cancers
(HNPCC) cancer, found in relatively younger patients
(mean age of 45), is associated with overall improved
survival compared with CRC in the elderly (22, 23).
Our dataset included 30 patients 60 years of age or
less. However, all but four patients were above
45 years of age. Thus, they do not fit to characteristics
for HNPCC patients. Evaluation of microsatellite insta-
bility status would help classifying these patients into
the HNPCC group. However, after closer analysis of
the patient’s age, such an approach would only pro-
duce data on mismatch repair genes in few patients
and the results would not be statistically sound.
Although a high-frequency of MSI (MSI-H) was report-
ed to characterize most HNPCC cases, MSI-H was also
found in non-HNPCC cases (24).
Our data showing significantly increased serum
IGF-I values can underlie the acceleration of tumor
growth in younger patients. As IGF-I induces anabolic
processes, it is not surprising that IGF-I significantly
increases in the sera of men with CRC that usually
develop greater muscle mass compared with women
with CRC. It has been reported that low caloric diet
and physical effort could greatly decrease serum IGF-I
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in rodents and significantly slow down development
of neoplasms in p53 null homozygous mice and p53
heterozygous mice (25).
If 4-nitroquinoline 1-oxide damaged DNA, IGF-I
switched on extranuclear transport and a proteasomic
mdm2-dependent decomposition of p53 in the cyto-
plasm of NIH-3T3 cells that overexpressed IGF-IRs
(NWTb3 cells). IGF-I indirectly abolished p53-depend-
ent induction of p21WAF1 that stopped the cell cycle
in G1 phase. The downregulation of p53 did not pre-
serve all DNA abnormalities in descendant cells since
IGF-I activated an ERCC-1 gene which mediated
repairs to DNA damage (26, 27). Overexpression of
p53 was usually observed when this protein was inac-
tive due to mutations (28). This mutant p53 could be
a target for an increased degradation of this protein
by IGF-I. Therefore, IGF-I dependent upregulation of
VEGF expression4 might be reversed as wild-type p53
decreases VEGF expression (29). However, mutant
p53 upregulated VEGF (30, 31). This could explain
the trend toward a highly significant negative correla-
tion between IGF-I and VEGF. Concerning knockout
of p53 action, it is not surprising that IGF-I accelerated
oncogenesis of murine mammary tumors (27). IGF-I
prolonged the life span of cells via enhancement of
Bcl-2 production and increases in the Bcl-2-to-Bax
protein ratio, which is a consequence of mdm2-
dependent decreases in p53 activity (32). The statis-
tically significant differences that indicated negative
correlation between serum IGF-I and p53 agreed with
previously reported IGF-I dependent attenuation of
p53. In a previous study (13), we inferred that there
is some correlation between IGF-I and p53 in colorec-
tal cancer. In the current paper, we present a detailed
comparison of IGF-I with p53 in patients with CRC. In
cancer patients, p53 was commonly mutated and this
mutant protein induced overexpression of IGF-IR on
malignant cells (33). Therefore, even decreased con-
centrations of IGF-I in serum was enough to stimulate
malignant cells by IGF-IR due to upregulation of the
receptor.
Regarding the impact of these proteins on the prog-
nosis of CRC, it is well known that VEGF is a well-
established indicator of poor survival. VEGF measur-
ed in preoperative serum was a significant predictor
of tumor recurrence in patients with CRC (34). We
demonstrated that CRC patients with higher serum
VEGF survived for shorter periods of time com-
pared with patients with VEGF concentrations that
were lower than the highest value for the control
group. To our knowledge, this comparison is the first
to be observed in patients with CRC. Our results are
consistent with other publications that reported on
the negative prognostic significance of VEGF in CRC
(35, 36).
The tendency toward negative correlation between
serum concentrations of IGF-I and p53 seemed to con-
firm indirectly, in association with certain clinicopa-
thological features, experiments on cell lines that
revealed IGF-I dependent attenuation of p53. Serum
concentrations of IGF-I and VEGF did not show posi-
tive correlation in cases of poorly differentiated
tumors (G3), and instead revealed a negative relation-
ship. In our opinion, this report adds further infor-
mation concerning the role of IGF-I. Further studies
to determine the nature of IGF-I in CRC are warranted
(37). In CRC, therapies are more effective if they are
combined (38). Studies have shown the role that IGF-
I and VEGF play in therapy (3, 38). Our study showed
the negative impact of VEGF on the prognosis of CRC
and justifies clinical application of VEGF antibodies.
However, our work did not show prognostic signifi-
cance for IGF-I and does not support use of IGF-1
antagonists for the management of CRC.
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